Acumen Pharmaceuticals Inc (NASDAQ: ABOS) Metrics That Matter Right Now

Acumen Pharmaceuticals Inc (NASDAQ:ABOS) shares, rose in value on Thursday, April 16, with the stock price down by -8.08% to the previous day’s close as strong demand from buyers drove the stock to $0.90.

Actively observing the price movement in the last trading, the stock closed the session at $0.98, falling within a range of $0.8686 and $1.005. The value of beta (5-year monthly) was 0.098. Referring to stock’s 52-week performance, its high was $3.92, and the low was $0.90. On the whole, ABOS has fluctuated by -29.07% over the past month.

With the market capitalization of Acumen Pharmaceuticals Inc currently standing at about $54.56 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-26.

Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that ABOS’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.

The stock’s technical analysis shows that the price of ABOS currently trading nearly -16.88% and -26.21% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 34.20, while the 7-day volatility ratio is showing 11.72% which for the 30-day chart, stands at 10.23%. Furthermore, Acumen Pharmaceuticals Inc (ABOS)’s beta value is 0.15, and its average true range (ATR) is 0.11.

A comparison of Acumen Pharmaceuticals Inc (ABOS) with its peers suggests the former has fared considerably weaker in the market. ABOS showed an intraday change of -8.08% in last session, and over the past year, it shrunk by -74.26%%.

Data on historical trading for Acumen Pharmaceuticals Inc (NASDAQ:ABOS) indicates that the trading volumes over the past 10 days have averaged 0.27 and over the past 3 months, they’ve averaged 243.82K. According to company’s latest data on outstanding shares, there are 60.09 million shares outstanding.

Nearly 26.90% of Acumen Pharmaceuticals Inc’s shares belong to company insiders and institutional investors own 62.14% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 1.65 million shares as on 2025-03-31, resulting in a short ratio of 8.07. According to the data, the short interest in Acumen Pharmaceuticals Inc (ABOS) stood at 366.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 1.79 million. The stock has fallen by -47.63% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the ABOS stock heading into the next quarter.

Most Popular